Gathering the record
Relay is organizing the evidence and source boundaries.
GnRH peptide hormone
Gonadorelin is synthetic GnRH, the hypothalamic signal that triggers pituitary LH and FSH release.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Gonadorelin is a synthetic copy of gonadotropin-releasing hormone, the brain signal that tells the pituitary gland to release two reproductive hormones.
Its short, controllable signal lets researchers test pituitary function and use carefully timed pulses to reproduce a missing natural rhythm in selected fertility disorders.
Decades of human endocrine research show predictable luteinizing-hormone and follicle-stimulating-hormone responses. Specialized pulsatile treatment has supported fertility in selected people with hypothalamic disorders. Diagnostic exposure and pump-based therapy answer different questions.
How nonstandard products, formulations, or delivery patterns compare with historical authorized products and validated pump programs remains uncertain. Brief, pulsatile, and continuous stimulation produce meaningfully different biology and cannot be treated as interchangeable schedules.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published human research evaluated pump-delivered pulses in women with hypothalamic amenorrhea, a condition caused by missing upstream reproductive signaling.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Established human endocrine evidence with product-, indication-, and delivery-pattern specificity.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
How any nonstandard formulation or delivery pattern compares with authorized products and validated pump-based regimens.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The treatment required a selected diagnosis, specialist monitoring, and a pump-based delivery system. Pulsatile fertility evidence cannot be transferred to arbitrary, brief, or continuous administration patterns. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
Decades of human endocrine testing and pulsatile-treatment research establish predictable LH/FSH responses in defined settings.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
How any nonstandard formulation or delivery pattern compares with authorized products and validated pump-based regimens.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
Brief or pulsatile GnRH exposure can stimulate gonadotropin secretion, while continuous GnRH-pathway stimulation produces different physiology. Diagnostic and pulsatile-fertility evidence cannot be generalized to arbitrary schedules.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Prospective human treatment study
Women with hypothalamic amenorrhea
Endpoints were not fully described in the current record.
Pulsatile GnRH restored gonadotropin signaling and ovulation in selected patients with hypothalamic amenorrhea.
Study administration: Not stated in the current record.
Limitations: Specialized pump-based delivery and selected diagnosis; not generalizable to other contexts.
Diagnostic endocrine study
Patients undergoing pituitary evaluation
Endpoints were not fully described in the current record.
Acute administration produced measurable LH and FSH responses used in endocrine assessment.
Study administration: Not stated in the current record.
Limitations: Diagnostic hormone response is not a therapeutic outcome.
Safety snapshot
Adverse effects and risks depend strongly on indication, sex, fertility context, delivery pattern, and product labeling; continuous and pulsatile exposure are not interchangeable.
Other human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
Adverse effects and risks depend strongly on indication, sex, fertility context, delivery pattern, and product labeling; continuous and pulsatile exposure are not interchangeable.
Other human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceThe current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 3925763
PMID 6402841